Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07690436 · ClinicalTrials.gov registry record
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
A clinical trial, sponsored by AstraZeneca.
- Not yet
- Registry status
- 500
- Enrollment target
NCT07690436 is a clinical trial that has not yet begun recruiting, run by AstraZeneca. The registered enrollment target is 500 participants.
The verdict
NCT07690436 has not yet begun recruiting, sponsored by AstraZeneca.
- NOT YET RECRUITING
- Registry status
- 500 participants
- Enrollment target
Study Summary
This multicenter pilot study will enroll adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure (HF) controls with documentation within the past 2 years that either excludes ATTR-CM or indicates a low probability of ATTR-CM. Ocular imaging and other study data will be collected to assess the feasibility of developing and preliminarily evaluating a machine learning model to discriminate ATTR-CM cases from HF controls without ATTR-CM.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2026-07-02 |
| Est. Completion | 2027-06-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07690436
The ClinicalTrials.gov registry entry for NCT07690436 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07690436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07690436 about?
NCT07690436 is a clinical study titled "Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM". This multicenter pilot study will enroll adult participants with a confirmed clinical diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and heart failure (HF) controls with documentation within the past 2 years that either excludes ATTR-CM or indicates a low probability of ATTR-CM. Ocular ...
What is the current status of trial NCT07690436?
This trial is currently not yet recruiting. The enrollment target is 500 participants. The study started on 2026-07-02. Estimated completion is 2027-06-03.
Who is sponsoring clinical trial NCT07690436?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.